



## Clinical trial results:

### A Randomized, Double-blind, Placebo-Controlled, Comparative Multicenter Phase 3 Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Injection for Prevention of Fracture in Ambulatory Postmenopausal Women With Severe Osteoporosis and at Risk of Fracture

#### Summary

EudraCT number	2010-022576-30
Trial protocol	EE LT DK CZ PL
Global end of trial date	07 October 2014

#### Results information

Result version number	v1 (current)
This version publication date	23 May 2020
First version publication date	23 May 2020

#### Trial information

##### Trial identification

Sponsor protocol code	BA058-05-003
-----------------------	--------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01343004
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Radius Health, Inc.
Sponsor organisation address	950 Winter Street, Waltham, MA, United States, 02451
Public contact	Associate Director, Clinical Operations, Radius Health, Inc., +1 6175514077, ncantacesso@radiuspharm.com
Scientific contact	VP, Oncology Clinical Development, Radius Health, Inc., +1 6175514086, mconlan@radiuspharm.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	10 December 2014
Is this the analysis of the primary completion data?	Yes
Primary completion date	07 October 2014
Global end of trial reached?	Yes
Global end of trial date	07 October 2014
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of this study was to determine the safety and efficacy of abaloparatide-subcutaneous (SC) 80 microgram ( $\mu\text{g}$ ) when compared to placebo for prevention of new vertebral fracture in otherwise healthy ambulatory postmenopausal women at risk of osteoporotic fracture.

Protection of trial subjects:

The study was conducted in accordance with the ethical principles that have their origins in the Declaration of Helsinki in its revised edition (Seoul, 2008), the guidelines for current Good Clinical Practice (GCP) International Conference on Harmonization (ICH) (CPMP/ICH/135/95), the US Food and Drug Administration (FDA) Code of Federal Regulations (CFR) (21 CFR Parts 50, 54, 56 and 312), Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) regulations (Argentinean Investigators only), and all other applicable local regulatory and ethical requirements.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	15 March 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 45
Country: Number of subjects enrolled	Brazil: 616
Country: Number of subjects enrolled	Czech Republic: 456
Country: Number of subjects enrolled	Denmark: 396
Country: Number of subjects enrolled	Estonia: 97
Country: Number of subjects enrolled	Hong Kong: 387
Country: Number of subjects enrolled	Lithuania: 84
Country: Number of subjects enrolled	Poland: 199
Country: Number of subjects enrolled	United States: 39
Country: Number of subjects enrolled	Romania: 144
Worldwide total number of subjects	2463
EEA total number of subjects	1376

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	464
From 65 to 84 years	1997
85 years and over	2

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

A total of 5268 patients were screened and 2463 patients were enrolled in the study.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Data analyst, Assessor

### Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	Placebo
------------------	---------

Arm description:

Placebo identical in appearance to BA058 study drug Placebo: Placebo 0 mcg subcutaneous daily

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in cartridge
Routes of administration	Subcutaneous use

Dosage and administration details:

Placebo identical in appearance to BA058 study drug.

Placebo 0 mcg subcutaneous daily

<b>Arm title</b>	BA058 80 mcg (abaloparatide)
------------------	------------------------------

Arm description:

BA058 80 mcg: BA058 80 mcg subcutaneous daily

Arm type	Experimental
Investigational medicinal product name	BA058 80 mcg (abaloparatide)
Investigational medicinal product code	
Other name	abaloparatide, Abaloparatide-SC
Pharmaceutical forms	Solution for injection in cartridge
Routes of administration	Subcutaneous use

Dosage and administration details:

BA058 80 mcg subcutaneous daily

<b>Arm title</b>	Teriparatide
------------------	--------------

Arm description:

Blinded until after randomization, then open-label teriparatide: teriparatide 20 mcg subcutaneous daily

Arm type	Active comparator
Investigational medicinal product name	teriparatide
Investigational medicinal product code	
Other name	Forteo, Forsteo
Pharmaceutical forms	Solution for injection in cartridge
Routes of administration	Subcutaneous use

Dosage and administration details:

Blinded until after randomization, then open-label.

Teriparatide 20 mcg subcutaneous daily

<b>Number of subjects in period 1</b>	Placebo	BA058 80 mcg (abaloparatide)	Teriparatide
Started	821	824	818
Completed	637	606	658
Not completed	184	218	160
Significant deterioration from baseline of BMD	12	1	1
Adverse event, serious fatal	5	3	3
Serious Intercurrent Illness	-	4	5
Hypersensitivity: aloparatide/placebo/teriparatide	1	-	-
Patient died during the study	5	3	2
Other than Specified	6	5	3
Hypercalcemia or Hypercalciuria	-	1	1
Refusal of Treatment	33	31	19
Administrative Reasons	-	1	-
Consent withdrawn by subject	48	47	45
Adverse event, non-fatal	48	86	50
Non-compliance	10	6	9
Treatment related SAE	-	-	2
Lost to follow-up	5	15	10
Protocol deviation	4	4	5
Inability to Complete Study Procedures	7	11	5

## Baseline characteristics

### Reporting groups

Reporting group title	Placebo
Reporting group description:	
Placebo identical in appearance to BA058 study drug Placebo: Placebo 0 mcg subcutaneous daily	
Reporting group title	BA058 80 mcg (abaloparatide)
Reporting group description:	
BA058 80 mcg: BA058 80 mcg subcutaneous daily	
Reporting group title	Teriparatide
Reporting group description:	
Blinded until after randomization, then open-label teriparatide: teriparatide 20 mcg subcutaneous daily	

Reporting group values	Placebo	BA058 80 mcg (abaloparatide)	Teriparatide
Number of subjects	821	824	818
Age categorical			
Units: Subjects			
<65 years	161	152	151
65 to <75 years	512	517	503
>=75 years	148	155	164
Age Continuous			
Units: years			
arithmetic mean	68.7	68.9	68.8
standard deviation	± 6.5	± 6.5	± 6.6
Gender, Male/Female			
Units:			
Female	821	824	818
Male	0	0	0

Reporting group values	Total		
Number of subjects	2463		
Age categorical			
Units: Subjects			
<65 years	464		
65 to <75 years	1532		
>=75 years	467		
Age Continuous			
Units: years			
arithmetic mean			
standard deviation	-		
Gender, Male/Female			
Units:			
Female	2463		
Male	0		

## End points

### End points reporting groups

Reporting group title	Placebo
Reporting group description:	
Placebo identical in appearance to BA058 study drug Placebo: Placebo 0 mcg subcutaneous daily	
Reporting group title	BA058 80 mcg (abaloparatide)
Reporting group description:	
BA058 80 mcg: BA058 80 mcg subcutaneous daily	
Reporting group title	Teriparatide
Reporting group description:	
Blinded until after randomization, then open-label teriparatide: teriparatide 20 mcg subcutaneous daily	

### Primary: Number of Participants with New Vertebral Fractures at 18 Months

End point title	Number of Participants with New Vertebral Fractures at 18 Months
End point description:	
Modified intent-to-treat (MITT) population included all patients with pre-treatment and end-of-treatment evaluable radiologic assessment (spine X-ray).	
End point type	Primary
End point timeframe:	
18 months	

End point values	Placebo	BA058 80 mcg (abaloparatide)	Teriparatide	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	711	690	717	
Units: participants	30	4	6	

### Statistical analyses

Statistical analysis title	Placebo versus BA058 80 mcg (Abaloparatide)
Comparison groups	Placebo v BA058 80 mcg (abaloparatide)
Number of subjects included in analysis	1401
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	Fisher exact

Statistical analysis title	Placebo versus Teriparatide
Comparison groups	Placebo v Teriparatide

Number of subjects included in analysis	1428
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	Fisher exact

### Secondary: Percent Change in Bone Mineral Density (BMD) of Lumbar Spine from Baseline to 18 Months

End point title	Percent Change in Bone Mineral Density (BMD) of Lumbar Spine from Baseline to 18 Months
-----------------	---

End point description:

Intent-to-treat population included all patients who were randomized into the study by assigning the randomized study medication kit on Day 1. Baseline BMD data were missing for some patients; the method of last observation carried forward (LOCF) was used to impute missing data.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and 18 months

End point values	Placebo	BA058 80 mcg (abaloparatide)	Teriparatide	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	821	823	818	
Units: percent change from baseline				
arithmetic mean (standard deviation)	0.48 (± 3.82)	9.20 (± 7.54)	9.12 (± 6.28)	

### Statistical analyses

<b>Statistical analysis title</b>	Placebo versus BA058 80 mcg (Abaloparatide)
Comparison groups	Placebo v BA058 80 mcg (abaloparatide)
Number of subjects included in analysis	1644
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	ANCOVA

<b>Statistical analysis title</b>	BA058 80 mcg (Abaloparatide) versus Teriparatide
Comparison groups	BA058 80 mcg (abaloparatide) v Teriparatide



Number of subjects included in analysis	1641
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.8155
Method	ANCOVA

<b>Statistical analysis title</b>	Placebo versus Teriparatide
Comparison groups	Placebo v Teriparatide
Number of subjects included in analysis	1639
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	ANCOVA

### Secondary: Percent Change in Bone Mineral Density (BMD) of Total Hip from Baseline to Month 18

End point title	Percent Change in Bone Mineral Density (BMD) of Total Hip from Baseline to Month 18
End point description: Intent-to-treat population included all patients who were randomized into the study by assigning the randomized study medication kit on Day 1. Baseline BMD data were missing for some patients; the method of LOCF was used to impute missing data.	
End point type	Secondary
End point timeframe: Baseline and 18 months	

End point values	Placebo	BA058 80 mcg (abaloparatide)	Teriparatide	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	820	822	818	
Units: percent change				
arithmetic mean (standard deviation)	-0.08 (± 2.77)	3.44 (± 3.51)	2.81 (± 3.33)	

### Statistical analyses

<b>Statistical analysis title</b>	Placebo versus BA058 80 mcg (Abaloparatide)
Comparison groups	Placebo v BA058 80 mcg (abaloparatide)

Number of subjects included in analysis	1642
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	ANCOVA

<b>Statistical analysis title</b>	Placebo versus Teriparatide
Comparison groups	Placebo v Teriparatide
Number of subjects included in analysis	1638
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	ANCOVA

<b>Statistical analysis title</b>	BA058 80 mcg (Abaloparatide) versus Teriparatide
Comparison groups	BA058 80 mcg (abaloparatide) v Teriparatide
Number of subjects included in analysis	1640
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	ANCOVA

## Secondary: Percent Change in Bone Mineral Density (BMD) of Femoral Neck from Baseline to Month 18

End point title	Percent Change in Bone Mineral Density (BMD) of Femoral Neck from Baseline to Month 18
-----------------	--

End point description:

Intent-to-treat population included all patients who were randomized into the study by assigning the randomized study medication kit on Day 1. Baseline BMD data were missing for some patients; the method of LOCF was used to impute missing data.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and 18 months

<b>End point values</b>	Placebo	BA058 80 mcg (abaloparatide)	Teriparatide	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	820	822	818	
Units: percent change				
arithmetic mean (standard deviation)	-0.44 (± 3.57)	2.90 (± 4.21)	2.26 (± 3.57)	

### Statistical analyses

<b>Statistical analysis title</b>	Placebo versus BA058 80 mcg (Abaloparatide)
Comparison groups	Placebo v BA058 80 mcg (abaloparatide)
Number of subjects included in analysis	1642
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	ANCOVA

<b>Statistical analysis title</b>	Placebo versus Teriparatide
Comparison groups	Placebo v Teriparatide
Number of subjects included in analysis	1638
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	ANCOVA

<b>Statistical analysis title</b>	BA058 80 mcg (Abaloparatide) versus Teriparatide
Comparison groups	BA058 80 mcg (abaloparatide) v Teriparatide
Number of subjects included in analysis	1640
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0004
Method	ANCOVA

### Secondary: Number of Participants with Non-vertebral Fractures at 18 Months

End point title	Number of Participants with Non-vertebral Fractures at 18 Months
End point description: Intent-to-treat population included all patients who were randomized into the study by assigning the randomized study medication kit on Day 1.	
End point type	Secondary
End point timeframe: 18 months	

<b>End point values</b>	Placebo	BA058 80 mcg (abaloparatide)	Teriparatide	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	821	824	818	
Units: Participants	33	18	24	

### Statistical analyses

<b>Statistical analysis title</b>	Placebo versus BA058 80 mcg (Abaloparatide)
Comparison groups	Placebo v BA058 80 mcg (abaloparatide)
Number of subjects included in analysis	1645
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0318
Method	Chi-squared

<b>Statistical analysis title</b>	Placebo versus Teriparatide
Comparison groups	Placebo v Teriparatide
Number of subjects included in analysis	1639
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.2304
Method	Chi-squared

<b>Statistical analysis title</b>	BA058 80 mcg (Abaloparatide) versus Teriparatide
Comparison groups	BA058 80 mcg (abaloparatide) v Teriparatide
Number of subjects included in analysis	1642
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.3361
Method	Chi-squared

### Secondary: Number of Treatment-Emergent Adverse Events Associated with Hypercalcemia at 18 Months

End point title	Number of Treatment-Emergent Adverse Events Associated with Hypercalcemia at 18 Months
-----------------	--

End point description:

Safety population included all patients who received 1 or more doses of study medication.

End point type	Secondary
End point timeframe:	
18 months	

<b>End point values</b>	Placebo	BA058 80 mcg (abaloparatide)	Teriparatide	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	820	822	818	
Units: Hypercalcemic events	5	15	34	

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Baseline up to 18 months

Adverse event reporting additional description:

Individual number of occurrences (events) are not available for this study. Therefore, the number of subjects exposed per preferred term are reported in the field for the number of occurrences (events).

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	17.1
--------------------	------

### Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Placebo identical in appearance to BA058 study drug Placebo: Placebo 0 mcg subcutaneous daily

Reporting group title	Teriparatide
-----------------------	--------------

Reporting group description:

Blinded until after randomization, then open-label teriparatide: teriparatide 20 mcg subcutaneous daily

Reporting group title	BA058 80 mcg (abaloparatide)
-----------------------	------------------------------

Reporting group description:

BA058 80 mcg: BA058 80 mcg subcutaneous daily

Serious adverse events	Placebo	Teriparatide	BA058 80 mcg (abaloparatide)
Total subjects affected by serious adverse events			
subjects affected / exposed	90 / 820 (10.98%)	82 / 818 (10.02%)	80 / 822 (9.73%)
number of deaths (all causes)	5	3	3
number of deaths resulting from adverse events	5	3	3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Breast cancer			
subjects affected / exposed	1 / 820 (0.12%)	6 / 818 (0.73%)	3 / 822 (0.36%)
occurrences causally related to treatment / all	0 / 1	0 / 6	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenocarcinoma of colon			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	2 / 822 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast cancer stage II			

subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Melanocytic naevus			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatic neoplasm			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenocarcinoma gastric			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angiolipoma			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Benign neoplasm of thyroid gland			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bile duct adenocarcinoma			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast neoplasm			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic leukaemia			

subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric neoplasm			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal carcinoma			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Invasive ductal breast carcinoma			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung adenocarcinoma			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung neoplasm malignant			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastatic malignant melanoma			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastatic squamous cell carcinoma			



subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myeloproliferative disorder			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine cancer			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatic carcinoma			
subjects affected / exposed	0 / 820 (0.00%)	2 / 818 (0.24%)	2 / 822 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Vascular disorders			
Intermittent claudication			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic dissection			
subjects affected / exposed	1 / 820 (0.12%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Essential hypertension			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	2 / 820 (0.24%)	2 / 818 (0.24%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 2	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive crisis			

subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Cholecystectomy			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colporrhaphy			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary angioplasty			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip arthroplasty			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint arthroplasty			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Knee arthroplasty			
subjects affected / exposed	1 / 820 (0.12%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteosynthesis			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectocele repair			

subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Removal of internal fixation			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toe operation			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	2 / 820 (0.24%)	1 / 818 (0.12%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest discomfort			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Sudden death			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Reproductive system and breast disorders			

Ovarian cyst			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	2 / 822 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postmenopausal haemorrhage			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	2 / 822 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine prolapse			
subjects affected / exposed	2 / 820 (0.24%)	1 / 818 (0.12%)	2 / 822 (0.24%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervical dysplasia			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystocele			
subjects affected / exposed	0 / 820 (0.00%)	3 / 818 (0.37%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine polyp			
subjects affected / exposed	1 / 820 (0.12%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Bronchiectasis			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Dyspnoea			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pulmonary embolism			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus polyp			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Allergic bronchitis			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary mass			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Weight decreased			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood glucose increased			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Body temperature increased			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchoscopy			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver function test abnormal			

subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Craniocerebral injury			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fibula fracture			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incisional hernia			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint dislocation			
subjects affected / exposed	2 / 820 (0.24%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ligament rupture			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Patella fracture			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative hernia			

subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal compression fracture			
subjects affected / exposed	0 / 820 (0.00%)	2 / 818 (0.24%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper limb fracture			
subjects affected / exposed	2 / 820 (0.24%)	1 / 818 (0.12%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ankle fracture			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Contusion			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Extradural haematoma			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	3 / 820 (0.37%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fracture displacement			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hand fracture			

subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower limb fracture			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar vertebral fracture			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meniscus injury			
subjects affected / exposed	3 / 820 (0.37%)	2 / 818 (0.24%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic fracture			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radius fracture			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			
subjects affected / exposed	1 / 820 (0.12%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ulna fracture			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wrist fracture			



subjects affected / exposed	0 / 820 (0.00%)	2 / 818 (0.24%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Myocardial ischaemia			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	2 / 822 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Supraventricular tachycardia			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	2 / 822 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardio-respiratory arrest			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Palpitations			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute coronary syndrome			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris			

subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina unstable			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure congestive			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiomyopathy			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery stenosis			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mitral valve stenosis			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus bradycardia			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			

subjects affected / exposed	2 / 820 (0.24%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Transient ischaemic attack			
subjects affected / exposed	2 / 820 (0.24%)	2 / 818 (0.24%)	2 / 822 (0.24%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depressed level of consciousness			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydrocephalus			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intracranial aneurysm			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radicular syndrome			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sciatica			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarchnoid haemorrhage			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			

subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tension headache			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carpal tunnel syndrome			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	1 / 820 (0.12%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness			
subjects affected / exposed	1 / 820 (0.12%)	2 / 818 (0.24%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	3 / 820 (0.37%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lacunar infarction			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Loss of consciousness			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VIIth nerve paralysis			

subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vestibular disorder			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Malculopathy			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal artery occlusion			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cataract			
subjects affected / exposed	2 / 820 (0.24%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Gastric Ulcer			

subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	2 / 822 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	3 / 820 (0.37%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal ulcer			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoids			
subjects affected / exposed	1 / 820 (0.12%)	1 / 818 (0.12%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			

subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Change of bowel habit			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulum			
subjects affected / exposed	1 / 820 (0.12%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocoele			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric haemorrhage			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	2 / 820 (0.24%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine polyp			

subjects affected / exposed	2 / 820 (0.24%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hepatobiliary disorders</b>			
Cholelithiasis			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	3 / 822 (0.36%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangitis			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bile duct stenosis			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biliary dyskinesia			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis acute			
subjects affected / exposed	1 / 820 (0.12%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Skin and subcutaneous tissue disorders</b>			
Dermatitis allergic			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug eruption			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypersensitivity vasculitis			



subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Hydronephrosis			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Calculus urinary			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Goitre			
subjects affected / exposed	1 / 820 (0.12%)	2 / 818 (0.24%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thyroid cyst			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Osteoarthritis			
subjects affected / exposed	1 / 820 (0.12%)	3 / 818 (0.37%)	3 / 822 (0.36%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	3 / 820 (0.37%)	1 / 818 (0.12%)	2 / 822 (0.24%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot deformity			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Spinal column stenosis			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal pain			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthralgia			
subjects affected / exposed	1 / 820 (0.12%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis reactive			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar spine stenosis			
subjects affected / exposed	1 / 820 (0.12%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal osteoarthritis			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spondylolisthesis			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Sepsis			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	2 / 822 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Urinary tract infection			

subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	2 / 822 (0.24%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiolitis			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopneumonia			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 820 (0.12%)	1 / 818 (0.12%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial infection			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dengue fever			

subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Helicobacter infection			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Localised infection			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nasopharyngitis			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paronychia			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis acute			
subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	1 / 820 (0.12%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			

subjects affected / exposed	1 / 820 (0.12%)	0 / 818 (0.00%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Metabolism and nutrition disorders</b>			
Hypoglycaemia			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	2 / 822 (0.24%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 820 (0.00%)	0 / 818 (0.00%)	1 / 822 (0.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gout			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			
subjects affected / exposed	0 / 820 (0.00%)	1 / 818 (0.12%)	0 / 822 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Placebo	Teriparatide	BA058 80 mcg (abaloparatide)
<b>Total subjects affected by non-serious adverse events</b>			
subjects affected / exposed	447 / 820 (54.51%)	456 / 818 (55.75%)	492 / 822 (59.85%)
<b>Vascular disorders</b>			
Hypertension			
subjects affected / exposed	52 / 820 (6.34%)	41 / 818 (5.01%)	59 / 822 (7.18%)
occurrences (all)	52	41	59
<b>Cardiac disorders</b>			
Palpitations			
subjects affected / exposed	3 / 820 (0.37%)	13 / 818 (1.59%)	42 / 822 (5.11%)
occurrences (all)	3	13	42
<b>Nervous system disorders</b>			

Dizziness subjects affected / exposed occurrences (all)	50 / 820 (6.10%) 50	59 / 818 (7.21%) 59	82 / 822 (9.98%) 82
Headache subjects affected / exposed occurrences (all)	49 / 820 (5.98%) 49	51 / 818 (6.23%) 51	62 / 822 (7.54%) 62
Gastrointestinal disorders			
Constipation subjects affected / exposed occurrences (all)	42 / 820 (5.12%) 42	34 / 818 (4.16%) 34	36 / 822 (4.38%) 36
Nausea subjects affected / exposed occurrences (all)	25 / 820 (3.05%) 25	42 / 818 (5.13%) 42	68 / 822 (8.27%) 68
Renal and urinary disorders			
Hypercalciuria subjects affected / exposed occurrences (all)	74 / 820 (9.02%) 74	102 / 818 (12.47%) 102	93 / 822 (11.31%) 93
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	80 / 820 (9.76%) 80	70 / 818 (8.56%) 70	71 / 822 (8.64%) 71
Back pain subjects affected / exposed occurrences (all)	81 / 820 (9.88%) 81	58 / 818 (7.09%) 58	69 / 822 (8.39%) 69
Pain in extremity subjects affected / exposed occurrences (all)	49 / 820 (5.98%) 49	42 / 818 (5.13%) 42	40 / 822 (4.87%) 40
Infections and infestations			
Influenza subjects affected / exposed occurrences (all)	39 / 820 (4.76%) 39	34 / 818 (4.16%) 34	52 / 822 (6.33%) 52
Nasopharyngitis subjects affected / exposed occurrences (all)	66 / 820 (8.05%) 66	52 / 818 (6.36%) 52	48 / 822 (5.84%) 48
Upper respiratory tract infection			

subjects affected / exposed	63 / 820 (7.68%)	73 / 818 (8.92%)	68 / 822 (8.27%)
occurrences (all)	63	73	68
Urinary tract infection			
subjects affected / exposed	38 / 820 (4.63%)	41 / 818 (5.01%)	43 / 822 (5.23%)
occurrences (all)	38	41	43

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
21 October 2011	<p>The protocol was amended to:</p> <ul style="list-style-type: none"><li>• modify the "Inclusion Criteria" section of the synopsis to clarify that patients who had participated in a clinical study of any novel unapproved medication in the past 12 months would be excluded from participation in BA058-005-03 unless they had received placebo.</li><li>• to allow patients who might have been considered for the study but were ineligible because of recent or current use of thiazides to be considered for enrollment after activation of this amendment</li><li>• increase the time allowed for screening procedures to facilitate sample transport and reporting, and repeat samples, and</li><li>• provide clarification on a number of questions arising from participating sites.</li></ul> <p>These modifications did not impact the conduct of the study, but rather clarified certain aspects of the study conduct, such as</p> <ul style="list-style-type: none"><li>– to clarify the timing of post-dose assessment of serum calcium levels,</li><li>– to allow retesting of serum 25 hydroxy vitamin D and PTH levels after vitamin D supplementation</li><li>– to clarify that albumin-corrected calcium will be used for assessment of serum calcium, both in safety and PD assessments, and</li><li>– to clarify that ionized calcium levels can be considered in assessing eligibility.</li></ul>
05 July 2012	<p>The following modifications were made to the protocol:</p> <ul style="list-style-type: none"><li>• Pre- and post-study renal CT scans in patients in selected centers was added; the previous version of the protocol required only post-study renal CT scans.</li><li>• A bone biopsy was added for teriparatide patients; the previous version of the protocol required bone biopsies for patients in the abaloparatide and placebo arms.</li><li>• A modification of the description of the Extension Study (Protocol BA058-05-005 [NCT01657162]) was made. The revised Study BA058-05-005 offered patients receiving abaloparatide/placebo treatment an additional six months of osteoporosis care, including recommended treatment with alendronate, as appropriate. The previous version of the Extension Study called for an additional six months of abaloparatide followed by 24 months of treatment with a bisphosphonate.</li><li>• A paragraph was added to describe the results of an ongoing rat carcinogenicity study with abaloparatide.</li><li>• A requirement was added that subjects who experience a clinical fracture during the study and elect to continue to participate would need to provide re-consent prior to continuing in the study.</li></ul>
31 March 2014	<p>The following modifications were made to the protocol:</p> <ul style="list-style-type: none"><li>• The name of BA058 was changed to abaloparatide throughout the document.</li><li>• A new Sponsor Medical Monitor/Study Safety Officer was added.</li><li>• Clarifications were made to more accurately describe the sequence of procedures in the protocol.</li><li>• Modifications were made to more clearly define how incident vertebral and nonvertebral fractures were diagnosed.</li><li>• Modifications were made to clarify that the hypercalcemia algorithm is based on pre- not post-dose serum calcium.</li><li>• Modifications were made to clarify the patient populations to be analyzed.</li><li>• Clarification of the definition of a protocol violation was added to align the protocol with Radius' Protocol Deviation/Violation Procedure Manual (Version 3.0, 1 October 2012).</li><li>• Clarification of the definition of a protocol deviation was added to align the protocol with Radius' Protocol Deviation/Violation Procedure Manual (Version 3.0, 1 October 2012).</li></ul>

Notes:



---

## **Interruptions (globally)**

Were there any global interruptions to the trial? No

## **Limitations and caveats**

None reported